Is the breast cancer drug tamoxifen being sold as a bodybuilding dietary supplement?

Michael Evans-Brown; Andreas Kimergård; Jim McVeigh; Martin Chandler; Simon D Brandt

doi:10.1136/bmj.g1476

Is the breast cancer drug tamoxifen being sold as a bodybuilding dietary supplement?

Michael Evans-Brown
, Andreas Kimergård
, Jim McVeigh
, Martin Chandler
, Simon D Brandt

Sport, Exercise and Rehabilitation Sciences

Research output: Contribution to journal › Letter › peer-review

13 Citations (Scopus)

Original language	English
Article number	g1476
Number of pages	2
Journal	BMJ
Volume	348
DOIs	https://doi.org/10.1136/bmj.g1476
Publication status	Published - 12 Feb 2014

Keywords

Dietary Supplements
Gynecomastia/prevention & control
Humans
Tamoxifen/analysis
Weight Lifting

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/bmj.g1476Licence: None: All rights reserved

https://doi.org/10.1136/bmj.g1476Licence: None: All rights reserved

Cite this

@article{11932c03ac644f459af57022a6d75094,

title = "Is the breast cancer drug tamoxifen being sold as a bodybuilding dietary supplement?",

keywords = "Dietary Supplements, Gynecomastia/prevention \& control, Humans, Tamoxifen/analysis, Weight Lifting",

author = "Michael Evans-Brown and Andreas Kimerg{\aa}rd and Jim McVeigh and Martin Chandler and Brandt, \{Simon D\}",

year = "2014",

month = feb,

day = "12",

doi = "10.1136/bmj.g1476",

language = "English",

volume = "348",

journal = "BMJ",